News Releases

Latest News Releases

Oct 21, 2026
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Download
Facebook Twitter LinkedIn Email this page
Oct 14, 2026
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Download
Facebook Twitter LinkedIn Email this page
Oct 14, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Download
Facebook Twitter LinkedIn Email this page
Sep 10, 2026
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Download
Facebook Twitter LinkedIn Email this page
Sep 02, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
Facebook Twitter LinkedIn Email this page
Aug 05, 2026
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Download
Facebook Twitter LinkedIn Email this page
Jun 02, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Download
Facebook Twitter LinkedIn Email this page
Jun 01, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
Facebook Twitter LinkedIn Email this page
May 07, 2026
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Download
Facebook Twitter LinkedIn Email this page
May 07, 2026
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Download
Facebook Twitter LinkedIn Email this page

Quick access to common resources

Frequently Asked Questions Frequent questions about owning stock in Entrada. SEC Filings View current and past SEC filings in various easy-to-access file formats. Events & Presentation View our latest events and presentation.